Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

1.16
+0.04003.57%
Post-market: 1.180.0195+1.68%19:44 EDT
Volume:2.79M
Turnover:3.22M
Market Cap:223.88M
PE:-4.49
High:1.17
Open:1.12
Low:1.12
Close:1.12
52wk High:3.36
52wk Low:0.8800
Shares:193.00M
Float Shares:154.00M
Volume Ratio:0.73
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2583
EPS(LYR):-1.2551
ROE:-249.75%
ROA:-63.44%
PB:-47.12
PE(LYR):-0.92

Loading ...

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Yesterday

BRIEF-Humacyte Submits Marketing Authorization Application For Symvess® In Israel For Vascular Trauma Repair

Reuters
·
Yesterday

Humacyte submits Symvess marketing authorization application in Israel

Reuters
·
Yesterday

Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

THOMSON REUTERS
·
Yesterday

Humacyte Management to Present at TD Cowen Annual Healthcare Conference and Barclays Global Healthcare Conference

Reuters
·
Mar 02

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 19

Humacyte Presents 36-Month Symvess Durability and Safety Data From V005 Trial at VESS 2026

Reuters
·
Feb 18

Why Humacyte (HUMA) Is Up 5.1% After New DoD Funding Backs Symvess Trauma Use

Simply Wall St.
·
Feb 12

Humacyte (HUMA) Valuation Check As DoD Funding Highlights Battlefield Vascular Repair Potential

Simply Wall St.
·
Feb 10

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 10

Humacyte Shares Climb After Pentagon Issues Funding for Vascular Repair Tech

Dow Jones
·
Feb 10

Press Release: Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Dow Jones
·
Feb 09

Humacyte Inc - Symness Is Only FDA-Approved Bioengineered Blood Vessel

THOMSON REUTERS
·
Feb 09

Humacyte Is Maintained at Buy by Benchmark

Dow Jones
·
Jan 21

Humacyte price target lowered to $10 from $11 at Benchmark

TIPRANKS
·
Jan 21

Benchmark Co. Sticks to Its Buy Rating for Humacyte (HUMA)

TIPRANKS
·
Jan 21

While institutions invested in Humacyte, Inc. (NASDAQ:HUMA) benefited from last week's 10% gain, retail investors stood to gain the most

Simply Wall St.
·
Jan 13

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 08

Humacyte Reports Symvess Reduces Costly Complications in Extremity Arterial Injury Repair

Reuters
·
Jan 08

BRIEF-Humacyte Inc Announces Planned Marketing Authorization Application For Symvess In Israel

Reuters
·
Jan 05